Skip to content

Sweet Corn and Carotenoids

Effects of Sweet Corn Intake on Carotenoid Levels and Gastrointestinal Wellness

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06892444
Enrollment
40
Registered
2025-03-24
Start date
2025-05-14
Completion date
2026-12-31
Last updated
2026-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carotenoids

Keywords

sweet corn, lutein, zeaxanthin, carotenoid

Brief summary

This study will assess the effect of daily yellow and white sweet corn intake on serum lutein and zeaxanthin concentrations. Skin carotenoid levels using the Veggie Meter will be assessed, and gastrointestinal symptoms and changes in fecal microbiota during a 4-week intervention period will be monitored.

Interventions

DIETARY_SUPPLEMENTYellow Sweet Corn

Participants will consume 1.5 cups daily of yellow or white canned sweet corn.

DIETARY_SUPPLEMENTWhite Sweet Corn

1.5 cups daily of canned yellow sweet corn

Sponsors

University of Florida
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* Adults ≥ 18 years of age * Able to provide written consent in English * Baseline Veggie Meter score of ≤ 300 (Scale from 0 to 850) * Willing to adhere to study procedures

Exclusion criteria

* Baseline Veggie Meter score of \>300 * Corn allergy * Current use of laxatives or antidiarrheal medications * Previously or currently being treated for intestinal disease, including irritable bowel syndrome, Crohn's disease, ulcerative colitis, celiac disease, or gastrointestinal cancer * Previous gastrointestinal surgery (e.g., gastric bypass, fundoplication, bowel resection) * Current cancer treatment * Current pregnancy * Vegetarian diet * Elite athletes or long-distance runners. * Use of antibiotic drugs within 1 month of the screening visit.

Design outcomes

Primary

MeasureTime frameDescription
Serum concentration of lutein + zeaxanthin28 daysSum of serum concentrations of lutein and zeaxanthin.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 14, 2026